FOXO4-DRI 10mg
The Senolytic Peptide That Eliminates Aging Senescent Cells
FOXO4-DRI is a D-retro-inverso peptide that disrupts the FOXO4-p53 interaction in senescent cells, triggering apoptosis specifically in these aged, harmful cells without affecting healthy tissue. It is one of the most exciting tools in senolytic longevity research.
The Senolytic Peptide That Eliminates Aging Senescent Cells
Senescent cells accumulate with age and secrete the SASP (senescence-associated secretory phenotype), driving chronic inflammation and tissue dysfunction. FOXO4-DRI breaks the FOXO4-p53 survival signal in these cells, inducing targeted apoptosis and reducing SASP burden.
As one of the most studied compounds in the longevity research space, FOXO4-DRI has attracted sustained scientific interest across Senolytic longevity research, SASP reduction studies, Aging hallmark investigation. Peer-reviewed evidence indicates that reduces senescent cell burden in aging mice, which has positioned FOXO4-DRI as a reference standard for researchers exploring senolytic longevity research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
FOXO4-DRI Documented Benefits: 4 Documented Mechanisms
Targeted Senolysis
Selectively induces apoptosis in senescent cells while leaving healthy tissue unaffected.
SASP Reduction
Eliminates senescent cells that produce the inflammatory SASP driving age-related tissue damage.
Tissue Function Restoration
Animal studies show restored muscle strength, renal function, and fitness after FOXO4-DRI treatment.
Fur and Organ Rejuvenation
Preclinical models demonstrate reversal of aging phenotypes including fur regrowth and organ repair.
How FOXO4-DRI Works: Molecular Mechanism & Pathway
D-retro-inverso peptide disrupting FOXO4-p53 binding in senescent cells, removing the survival signal and triggering caspase-mediated apoptosis.
The 4 primary research pathways identified for FOXO4-DRI — Targeted Senolysis, SASP Reduction, Tissue Function Restoration — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that restores fitness and renal function in preclinical studies, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, FOXO4-DRI's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
FOXO4-DRI is routinely studied alongside Epitalon and NAD+ in longevity-focused compound panels. Researchers investigating senolytic longevity research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that selectively cytotoxic to senescent vs healthy cells has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All FOXO4-DRI research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Reduces senescent cell burden in aging mice
- Restores fitness and renal function in preclinical studies
- Selectively cytotoxic to senescent vs healthy cells
Ideal For
- Senolytic longevity research
- SASP reduction studies
- Aging hallmark investigation
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on FOXO4-DRI. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Reduces senescent cell burden in aging mice
Restores fitness and renal function in preclinical studies
Selectively cytotoxic to senescent vs healthy cells
Third-Party Verified Every Batch
Each vial of FOXO4-DRI is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
